CAMK2G and hypertensive disorder: A pharmacological inhibitor (KN-93) of the calcium/calmodulin-dependent kinase (CaMKII)60 and transgenic expression of CaMKII peptide inhibitor in VSMC have been reported to attenuate hypertension after angiotensin II infusion by controlling baroreceptor function61.